Regeneron (REGN) Tops Q3 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 4% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Leerink Partners Reiterated Outperform Following Regeneron's (REGN) 3Q Beat
November 5, 2015 8:07 AM ESTLeerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings report. REGN reported revenues and EPS of $1.14bn and $1.82, respectively, thereby beating consensus estimates of $1.79 and $1.64. REGN tightened its 2015 non-GAAP R&D guidance... More
Regeneron (REGN) Reports Strong Eylea Sales; Cowen Reiterates Market Perform
November 4, 2015 3:55 PM ESTCowen reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $575.00 (from $550.00), following the company's 3Q15 earnings report. Eylea sales of $734MM were well ahead of consensus of $683MM and 2015 guidance was increased again. Adoption... More
